Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Valeant

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Valeant's Japan sales performance.

valeant

AbbVie risankizumab trials set up psoriasis filing - and a market battle

AbbVie risankizumab trials set up psoriasis filing - and a market battle Since its debut in 2015 Cosentyx has been joined by IL-17 inhibitors from Eli Lilly and Valeant, while Johnson &Johnson has IL-23 blocker Tremfya (guselkumab) approved in the US

Pharma deals continue to slide

Pharma deals continue to slide $35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.

European Commission backs LEO Pharma’s Kyntheum

European Commission backs LEO Pharma’s Kyntheum The announcement follows the approval of brodalumab - marketed as Siliq by Valeant Pharmaceuticals - in the US for the same indication, but has come with a black box warning linking the drug

Audit exposes gaps in pharma's promises on trial transparency

Audit exposes gaps in pharma's promises on trial transparency At the other end of the scale lie Valeant, Sigma-Tau, Gilead, Esteve, Dainippon Sunitomo, Alkermes and Abbott - all of which scored zero on the policy transparency index.

Biosimilars eat into J&J's Remicade sales

Biosimilars eat into J&J's Remicade sales J&J now has an IL-23 inhibitor Tremfya (guselkumab) ready to take on Cosentyx and other IL-17-tageting competitors - Eli Lilly with Taltz (ixekizumab), and Valeant Pharmaceuticals with Siliq

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...